Overview

Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of the modified Conjunctival Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to treatment with a proven ocular anti-inflammatory medication, Prednisolone, assessed by the following measures: Chronic Allergic Inflammation assessed using confocal microscopy Ocular itching Conjunctival redness
Phase:
Phase 4
Details
Lead Sponsor:
ORA, Inc.
Treatments:
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Ophthalmic Solutions
Pharmaceutical Solutions
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate